CYTODYN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.143 USD | -2.05% |
|
-7.74% | -26.67% |
| Apr. 15 | CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
| Mar. 05 | Transcript : CytoDyn Inc. - Special Call |
Valuation
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 103.3 | 128.8 | 1,524 | 1,188 | 230.6 | 239.5 |
| Enterprise Value (EV) 1 | 102 | 134.4 | 1,525 | 1,218 | 263.2 | 272.5 |
| P/E ratio | -1.7 x | -1.89 x | -10 x | -7.22 x | -1.02 x | -2.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 867,096,417 x | - |
| EV / Revenue | - | - | - | - | 989,524,989 x | - |
| EV / EBITDA | -2.24 x | -2.46 x | -21 x | -13.1 x | -1.82 x | -6.74 x |
| EV / FCF | -6.92 x | -4.72 x | -31.3 x | -15.9 x | -2.56 x | -9.63 x |
| FCF Yield | -14.5% | -21.2% | -3.2% | -6.3% | -39.1% | -10.4% |
| Price to Book | -8.02 x | -14.4 x | -619 x | -56.6 x | -2.45 x | -2.2 x |
| Nbr of stocks (in thousands) | 212,083 | 329,396 | 514,734 | 625,286 | 718,528 | 915,072 |
| Reference price 2 | 0.4869 | 0.3910 | 2.960 | 1.900 | 0.3210 | 0.2617 |
| Announcement Date | 7/27/18 | 8/14/19 | 8/14/20 | 7/30/21 | 8/15/22 | 9/14/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | 0.266 | - |
| EBITDA 1 | -45.56 | -54.61 | -72.61 | -92.75 | -144.6 | -40.4 |
| EBIT 1 | -45.92 | -55.85 | -74.65 | -94.55 | -145.4 | -40.58 |
| Operating Margin | - | - | - | - | -54,663.16% | - |
| Earnings before Tax (EBT) 1 | -50.15 | -59.01 | -124.4 | -154.7 | -210.8 | -79.82 |
| Net income 1 | -50.15 | -56.19 | -124.4 | -154.7 | -210.8 | -79.82 |
| Net margin | - | - | - | - | -79,255.64% | - |
| EPS 2 | -0.2868 | -0.2065 | -0.2954 | -0.2632 | -0.3139 | -0.1037 |
| Free Cash Flow 1 | -14.75 | -28.48 | -48.74 | -76.66 | -102.9 | -28.3 |
| FCF margin | - | - | - | - | -38,680.17% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/27/18 | 8/14/19 | 8/14/20 | 7/30/21 | 8/15/22 | 9/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 5.63 | 1.07 | 29.5 | 32.6 | 33 |
| Net Cash position 1 | 1.23 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.1031 x | -0.0148 x | -0.3184 x | -0.2252 x | -0.8171 x |
| Free Cash Flow 1 | -14.8 | -28.5 | -48.7 | -76.7 | -103 | -28.3 |
| ROE (net income / shareholders' equity) | 703% | 509% | 2,184% | 1,316% | 365% | 78.3% |
| ROA (Net income/ Total Assets) | -443% | -271% | -131% | -64.7% | -113% | -125% |
| Assets 1 | 11.32 | 20.74 | 95.18 | 239 | 187.1 | 63.7 |
| Book Value Per Share 2 | -0.0600 | -0.0300 | -0 | -0.0300 | -0.1300 | -0.1200 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0300 | 0.0500 | 0.0100 | 0 |
| Capex | - | 0.03 | 0.04 | 0.12 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 7/27/18 | 8/14/19 | 8/14/20 | 7/30/21 | 8/15/22 | 9/14/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.67% | 142M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CYDY Stock
- Financials CytoDyn Inc.
